| Cross Timbers Hospice Inc 207 C Street Northwest, Ardmore, OK, 73401 | |
| (580) 223-0655 |
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| Name | Cross Timbers Hospice Inc |
|---|---|
| Location | 207 C Street Northwest, Ardmore, Oklahoma |
| Hospice ID | 371547 |
| Category | Freestanding Hospice |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| Accreditation Provider | The Joint Commission (TJC) |
| SSA county code | 090 |
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| NPI Number | 1669475513 |
| Organization Name | Cross Timbers Hospice, Inc |
| Address | 207 C St Nw Ardmore, Oklahoma, 73401 |
| Phone Number | (580)223-0655 |
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.4 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 98.6 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 97.5 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 65.4 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 98.6 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 89.9 | 93.3 |
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| Home Health Aides | 13 |
| Counselors | 2 |
| Licensed Practical or Vocational Nurses | 14 |
| Medical Social Workers | 4 |
| Physicians | 2 |
| Registered Nurses | 23 |
| Other Personnel | 16 |
| Total Employees | 74 |
|---|
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| Others | 60 |
| Total Volunteers | 60 |
|---|
News Archive
Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).
In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."
Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.
Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.
While public health authorities focus on the physical activity benefits of active play, a new study from the University of Montreal reveals that for children, playing has no goal - it is an end in itself, an activity that is fun, done alone or with friends, and it represents "an opportunity to experience excitement or pleasure, but also to combat boredom, sadness, fear, or loneliness."
› Verified 9 days ago
| Cross Timbers Hospice Inc Location: 207 C Street Northwest, Ardmore, Oklahoma, 73401 Phone: (580) 223-0655 |